CL2022003684A1 - Agentes de unión a lair-1 y métodos para su uso - Google Patents

Agentes de unión a lair-1 y métodos para su uso

Info

Publication number
CL2022003684A1
CL2022003684A1 CL2022003684A CL2022003684A CL2022003684A1 CL 2022003684 A1 CL2022003684 A1 CL 2022003684A1 CL 2022003684 A CL2022003684 A CL 2022003684A CL 2022003684 A CL2022003684 A CL 2022003684A CL 2022003684 A1 CL2022003684 A1 CL 2022003684A1
Authority
CL
Chile
Prior art keywords
binding agents
lair
methods
antibodies
compositions
Prior art date
Application number
CL2022003684A
Other languages
English (en)
Inventor
Yan Wang
Suzanne Christine Crawley
Bin Fan
Betty Chan Li
Lee Benjamin Rivera
James Robert Sissons
Jonathan Sitrin
Xuan Zhao
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of CL2022003684A1 publication Critical patent/CL2022003684A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona agentes de unión, tales como anticuerpos, que se unen específicamente a LAIR-1, incluido LAIR-1 humano, así como composiciones que comprenden los agentes de unión, y métodos para su uso. La descripción también proporciona polinucleótidos y vectores relacionados que codifican los agentes de unión y las células que comprenden los agentes de unión.
CL2022003684A 2020-06-22 2022-12-21 Agentes de unión a lair-1 y métodos para su uso CL2022003684A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063042299P 2020-06-22 2020-06-22
US202063122877P 2020-12-08 2020-12-08

Publications (1)

Publication Number Publication Date
CL2022003684A1 true CL2022003684A1 (es) 2023-07-28

Family

ID=76959074

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003684A CL2022003684A1 (es) 2020-06-22 2022-12-21 Agentes de unión a lair-1 y métodos para su uso

Country Status (15)

Country Link
US (1) US20220041711A1 (es)
EP (1) EP4168451A2 (es)
JP (1) JP2023532857A (es)
KR (1) KR20230039640A (es)
CN (2) CN116209676A (es)
AU (1) AU2021296168A1 (es)
BR (1) BR112022026284A2 (es)
CA (1) CA3187944A1 (es)
CL (1) CL2022003684A1 (es)
CO (1) CO2022018537A2 (es)
IL (1) IL299245A (es)
MX (1) MX2022016544A (es)
PE (1) PE20230839A1 (es)
TW (1) TW202216768A (es)
WO (1) WO2021262597A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230220076A1 (en) * 2021-12-21 2023-07-13 Ngm Biopharmaceuticals, Inc. Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody
WO2023173091A1 (en) * 2022-03-11 2023-09-14 Ngm Biopharmaceuticals, Inc. Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
WO2023215829A1 (en) * 2022-05-05 2023-11-09 Amgen Inc. Heteromultimer binding dll3 and cd3
WO2024067864A1 (en) * 2022-09-30 2024-04-04 Shanghai Junshi Biosciences Co., Ltd. Anti-lair1 antibodies and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102736A2 (en) * 2006-03-08 2007-09-13 Universitair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen.
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
SI2992017T1 (sl) 2013-05-02 2021-04-30 Anaptysbio, Inc. Protitelesa, usmerjena proti programirani smrti-1 (PD-1)
PL3478713T3 (pl) * 2016-06-30 2022-10-10 Prothena Biosciences Limited Kompozycje do leczenia amyloidozy
JP7152404B2 (ja) * 2017-01-02 2022-10-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌａｉｒ１抗体およびその使用

Also Published As

Publication number Publication date
JP2023532857A (ja) 2023-08-01
WO2021262597A9 (en) 2022-06-02
PE20230839A1 (es) 2023-05-19
IL299245A (en) 2023-02-01
WO2021262597A2 (en) 2021-12-30
WO2021262597A3 (en) 2022-02-24
KR20230039640A (ko) 2023-03-21
US20220041711A1 (en) 2022-02-10
CN116813777A (zh) 2023-09-29
TW202216768A (zh) 2022-05-01
MX2022016544A (es) 2023-04-05
CN116209676A (zh) 2023-06-02
CA3187944A1 (en) 2021-12-30
BR112022026284A2 (pt) 2023-03-07
AU2021296168A1 (en) 2023-02-02
EP4168451A2 (en) 2023-04-26
CO2022018537A2 (es) 2023-03-07

Similar Documents

Publication Publication Date Title
CO2022018537A2 (es) Agentes de unión a lair-1 y métodos para su uso
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
CL2022003004A1 (es) Agentes de unión a ilt y métodos para su uso
DOP2020000021A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
NI202000086A (es) Agentes vinculantes de psma y usos de los mismos
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
UY33850A (es) Anticuerpos anti ? cd38
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
CL2015002469A1 (es) Anticuerpos dirigidos contra il-33 y sus usos
UY38391A (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anti hla-g
CL2020002522A1 (es) Agentes de unión a c3 y métodos para su uso
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20150360A1 (es) Agentes de union de proteina de r-espondina humana (rsp03) y usos de los mismos
CL2021003343A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3.
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
UY38797A (es) Anticuerpos inmunomoduladores y métodos de uso de los mismos
CO2019006424A2 (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas
CO2023010208A2 (es) Proteínas de unión a psma y usos de estas
UY33274A (es) Proteínas de unión a basigina
CL2019002081A1 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas.
CL2020002680A1 (es) Anticuerpos para radionúclidos quelados
MX2020009022A (es) Uso de alcoxipirazoles como inhibidores de la nitrificacion.
AR122678A1 (es) Agentes de unión a lair-1 y métodos para su uso
AR121974A1 (es) Agentes de unión a ilt y métodos para su uso